Tuvatexib

The article explores the potential of VDA1275 both as a standalone therapy and in synergistic combination with traditional chemotherapy Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) This study marks an important milestone in our mission to develop therapies that overcome tumor resistance and enhance the effectiveness of existing treatments” — Dr. Max Herzberg LONDON, UNITED KINGDOM, June 10, 2025 / EINPresswire.com / -- Vidac Pharma , a clinical-stage biopharmaceutical company developing innovative cancer therapies, is pleased to announce the publication of a new peer-reviewed scientific article that explores the potential of its proprietary compound VDA1275—both as a standalone therapy and in synergistic combination with traditional chemotherapy. The article, published in "Journal of Nanomedicine& Biotherapeutic discovery" provides an in-depth look at the mechanism of action of VDA1275, a promising new drug candidate for the treatment of solid tumors. The study highlights VDA1275’s triple mechanism of action: • Reversal of the Warburg effect: VDA1275 disrupts excessive glycolysis in cancer cells, restoring normal cellular metabolism. • Reactivation of apoptosis: By reopening the mitochondrial pore, VDA1275 restores programmed cell death pathways that are often disabled in tumors. • Modulation of the tumor microenvironment (TME): VDA1275 reduces lactate production, creating a more favorable microenvironment that enhances the efficacy of chemotherapeutic agents and promotes a pro-immune response. This breakthrough adds to Vidac Pharma’s growing oncology pipeline. The company's lead drug candidate, Almavid™ (a proprietary formulation of Tuvatexib (VDA1102)), is currently undergoing advanced development for subcutaneous administration across multiple cancer types. VDA1275, designed for oral administration, complements Almavid™ and has demonstrated highly synergistic activity when used in combination with classical chemotherapy agents, as detailed in this collaborative research with HCS scientists. "We are excited to see the promising data on VDA1275’s unique mechanism and its potential to improve outcomes for cancer patients," said Dr. Max Herberg, Active Chairman & CEO at Vidac Pharma. "This study marks an important milestone in our mission to develop therapies that overcome tumor resistance and enhance the effectiveness of existing treatments." Vidac Pharma remains committed to advancing its innovative oncology programs and bringing new hope to patients worldwide. Max Herzberg / Sandra Gamzon Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Revolutionary cancer treatment demonstrates potential for Almavid™ Drug Candidate application in solid tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) We are optimistic about advancing Almavid™ into larger trials as we continue our mission to make cancer cells mortal again” — Dr. Max Herzberg LONDON, UNITED KINGDOM, May 28, 2025 / EINPresswire.com / -- Vidac Pharma , a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, today announced promising real-world pharmacokinetics results from the use of its investigational drug Almavid™, a proprietary subcutaneous formulation of VDA 1102 (Tuvatexib), in pediatric brain cancer patients. Administered to three pediatric patients with brain cancer, Almavid™ demonstrated exceptional pharmacokinetic properties, including high blood stability for over 24 hours, strong dose linearity, and sustained blood concentration levels across patients. These findings suggest that Almavid™ has strong potential as a broad-spectrum treatment for solid tumors, both as a monotherapy and in combination therapies. VDA 1102, the active ingredient in Almavid™, targets a fundamental mechanism in cancer metabolism by reversing the Warburg effect—a hallmark of cancer cell behavior first described by Nobel laureate Otto Warburg nearly a century ago. Unlike healthy cells, cancer cells exhibit heightened glycolysis even in the presence of oxygen. While this phenomenon has primarily been leveraged in diagnostics (e.g., PET scans), Vidac Pharma is the first company to translate this biological insight into a targeted therapeutic strategy. VDA 1102 works by disrupting the binding of hexokinase 2 (HK2), an enzyme overexpressed in cancer cells, to the mitochondrial voltage-dependent anion channel (VDAC1). This interaction blocks the natural process of programmed cell death (apoptosis), allowing cancer cells to persist and proliferate. By modifying HK2’s structure, VDA 1102 re-enables apoptosis, restoring normal cellular metabolism and promoting cancer cell death while modifying Tumor microenvironment to pro immune. This mechanism has already shown clinical promises. VDA 1102 previously demonstrated efficacy with minimal side effects in Phase 2 trials targeting two oncological skin conditions: Actinic Keratosis and Cutaneous T-Cell Lymphoma. “These latest results in our proprietary new formulation for Subcutaneous injections in pediatric patients highlight VDA 1102’s potential to become a transformational agent across a broad range of solid tumors,” said Dr Max Herzberg, Chairman of Vidac Pharma . “We are optimistic about advancing Almavid™ into larger trials as we continue our mission to make cancer cells mortal again.” Max Herzberg / Sandra Gamzon Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.